These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10541319)

  • 21. Long-term efficacy of pegylated recombinant human megakaryocyte growth and development factor in therapy of aplastic anemia.
    Yonemura Y; Miyake H; Asou N; Mitsuya H
    Int J Hematol; 2005 Nov; 82(4):307-9. PubMed ID: 16298819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; Kerzic P; McNiece I
    Stem Cells; 1997; 15(1):43-9. PubMed ID: 9007221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.
    Nakamura M; Toombs CF; Duarte IG; Ronson RS; Schmarkey LS; Katzmark SL; Robinson J; Dillehay DL; Vinten-Johansen J; Guyton RA
    Ann Thorac Surg; 1998 Oct; 66(4):1216-23. PubMed ID: 9800809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
    Basser RL
    Stem Cells; 1998; 16 Suppl 2():225-9. PubMed ID: 11012194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia.
    Vadhan-Raj S
    Semin Hematol; 2000 Apr; 37(2 Suppl 4):28-34. PubMed ID: 10831286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
    Honda K; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
    Bone Marrow Transplant; 2001 Aug; 28(4):329-34. PubMed ID: 11571503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
    Newland A
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
    Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice.
    Akahori H; Ozai M; Ida M; Shibuya K; Kato T; Miyazaki H
    Ther Apher; 1998 Feb; 2(1):58-64. PubMed ID: 10227790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.
    O'Malley CJ; Rasko JE; Basser RL; McGrath KM; Cebon J; Grigg AP; Hopkins W; Cohen B; O'Byrne J; Green MD; Fox RM; Berndt MC; Begley CG
    Blood; 1996 Nov; 88(9):3288-98. PubMed ID: 8896392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
    Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
    J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombopoietin from human embryonic kidney cells causes increased thrombocytopoiesis in sublethally irradiated mice.
    Carter CD; McDonald TP
    Radiat Res; 1992 Oct; 132(1):74-81. PubMed ID: 1410278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombopoietin from human embryonic kidney cells stimulates an increase in megakaryocyte size of sublethally irradiated mice.
    Carter CD; Schultz TW; McDonald TP
    Radiat Res; 1993 Jul; 135(1):32-9. PubMed ID: 8327658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombopoietin therapy increases platelet yields in healthy platelet donors.
    Kuter DJ; Goodnough LT; Romo J; DiPersio J; Peterson R; Tomita D; Sheridan W; McCullough J
    Blood; 2001 Sep; 98(5):1339-45. PubMed ID: 11520780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
    Zhang GL; Gao Y; Liu Y; Gu F; Su W; Qin Q; Chen JY; Zhang HH; Yang J; Liu XY
    Zhonghua Er Ke Za Zhi; 2017 Sep; 55(9):700-704. PubMed ID: 28881518
    [No Abstract]   [Full Text] [Related]  

  • 36. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
    Goodnough LT; Kuter DJ; McCullough J; Slichter SJ; DiPersio J; Romo J; Peterson R; Smith KJ; Raife T; Tomita D; Armstrong S
    Blood; 2001 Sep; 98(5):1346-51. PubMed ID: 11520781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.
    Harker LA; Roskos LK; Marzec UM; Carter RA; Cherry JK; Sundell B; Cheung EN; Terry D; Sheridan W
    Blood; 2000 Apr; 95(8):2514-22. PubMed ID: 10753829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome.
    Kizaki M; Miyakawa Y; Ikeda Y
    Br J Haematol; 2003 Sep; 122(5):764-7. PubMed ID: 12930386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
    Sheridan W; Menchaca D
    Stem Cells; 1998; 16 Suppl 2():193-8. PubMed ID: 11012191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo.
    Lannutti BJ; Gately ST; Quevedo ME; Soff GA; Paller AS
    Cancer Res; 1997 Dec; 57(23):5277-80. PubMed ID: 9393749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.